Cas:162650-77-3 ethaboxam manufacturer & supplier

Chemical Name:ethaboxam

CAS.NO:162650-77-3

Synonyms:ethaboxam;N-(α-Cyano-2-thienylmethyl)-4-ethyl-2-(ethylamino)-5-thiazolecarboxamide;T5SJ BYCN&MV- ET5N CSJ BM2 D2;N-(Cyano-2-thienylmethyl)-4-ethyl-2-(ethylamino)-5-thiazolecarboxamide;N-[cyano(thiophen-2-yl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide;5-Thiazolecarboxamide, N-(cyano-2-thienylmethyl)-4-ethyl-2-(ethylamino)-;(RS)-N-(α-cyano-2-thenyl)-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide;N-[Cyano(2-thienyl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide;Ethaboxam [ISO];rac-N-[(R)-cyano(thiophen-2-yl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide

Molecular Formula:C₁₄H₁₆N₄OS₂

Molecular Weight:320.433

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.3±0.1 g/cm3

Index of Refraction:1.643

PSA:141.01000

Exact Mass:320.076538

LogP:2.69

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethaboxam chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,rac-N-[(R)-cyano(thiophen-2-yl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(α-Cyano-2-thienylmethyl)-4-ethyl-2-(ethylamino)-5-thiazolecarboxamide Use and application,MV- ET5N CSJ BM2 D2 technical grade,usp/ep/jp grade.

Related News: The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers. ethaboxam manufacturer What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. ethaboxam supplier But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. ethaboxam vendor During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. ethaboxam factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.